Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma
Open Access
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a primary glial glioma that occurs in all age groups but predominates in children and is the main cause of solid tumor-related childhood mortality. Due to its rapid progression, the inability to operate and insensitivity to most chemotherapies, there is a lack of effective treatment methods in clinical practice for DIPG patients. The prognosis of DIPG patients is extremely poor, with a median survival time of no more than 12 months. In recent years, there have been continuous breakthroughs for immunotherapies in various hematological tumors and malignant solid tumors with extremely poor prognoses, which provides new insights into tumors without effective treatment strategies. Meanwhile, with the gradual development of stereotactic biopsy techniques, it is gradually becoming easier and safer to obtain live DIPG tissue, and the understanding of the immune properties of DIPG has also increased. On this basis, a series of immunotherapy studies of DIPG are under way, some of which have shown encouraging results. Herein, we review the current understanding of the immune characteristics of DIPG and critically reveal the limitations of current immune research, as well as the opportunities and challenges for immunological therapies in DIPG, hoping to clarify the development of novel immunotherapies for DIPG treatment.Keywords
Funding Information
- the National Key R&D Program of China (2019YFC1316104)
This publication has 83 references indexed in Scilit:
- The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expressionGenes & Development, 2013
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomasJournal of Neuro-Oncology, 2012
- Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomasNature Genetics, 2012
- Diffuse intrinsic pontine glioma: poised for progressFrontiers in Oncology, 2012
- Bone Marrow Mesenchymal Stem Cells Loaded With an Oncolytic Adenovirus Suppress the Anti-adenoviral Immune Response in the Cotton Rat ModelMolecular Therapy, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaJournal of Neuro-Oncology, 2009
- An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiformeMolecular Cancer Therapeutics, 2009
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003